Business Wire

Seoul Semiconductor Hosts European Symposium on “Human-Centric Lighting & Health”

Jaa

Seoul Semiconductor, a global innovator of LED products and technology, hosted a symposium featuring academics and industry insiders that focused on scientifically and objectively demonstrating the effects of light on health and circadian rhythm. Held on March 21 in conjunction with Light + Building 2018, the largest lighting exhibition in the world, Seoul Semiconductor’s symposium was entitled “Human-Centric Lighting & Health.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180329005388/en/

Scene from the SunLike Series LED Symposium held at the 2018 Light + Building Exhibition in Frankfur ...

Scene from the SunLike Series LED Symposium held at the 2018 Light + Building Exhibition in Frankfurt, Germany. (Photo: Business Wire)

The half-day symposium program consisted of several invited experts, including Professor Russell Foster from the University of Oxford, widely accepted as the leading authority in light, sleep, and circadian rhythm research; along with Dr. Manuel Spitschan from the University of Oxford, and Dr. Octavio L. Perez from Mount Sinai Hospital in New York. All three experts gave presentations on the effects of light on human health, and discussed the future direction of lighting.

According to Professor Foster, “Light not only allows us to perceive space, but also plays a critical role in enabling us to perceive time by controlling our circadian rhythm and sleep. To sustain a healthy and happy life, we must get the best sleep and keep our circadian rhythm at an optimum level. We also need to replace today’s artificial lighting systems that hinder our circadian rhythm with more human-centric lighting.”

In another presentation, Dr. Manuel Spitschan from the University of Oxford emphasized the impact of light on the body’s circadian rhythm, stating, “Light has an extremely significant impact on human eyes and brain, due to the photoreceptors in the retina. These receptors perceive red, green, and blue light, and accept the color spectrum in varying degrees.” Dr. Spitschan added, “In particular, intrinsically photosensitive retinal ganglion cells (ipRGC), deliver signals from light via a direct connection to the brain, and react more sensitively to blue light within a certain wavelength. When these cells are activated, it causes the body to inhibit the production of melatonin, a hormone that regulates sleep, therefore affecting the 24-hour circadian rhythm.”

Addressing the importance of sunlight in next-generation architecture standards, Dr. Octavio Perez from Mount Sinai Hospital in New York explained, “Typically, people who live in buildings with great lighting – in other words, buildings that get a lot of sunlight – are healthier and happier, compared to people living in artificially-lit indoor spaces. This is because artificial light features a spectrum that vastly differs from natural sunlight."

“Artificial light, such as fluorescent light and LEDs that emit a spectrum with irregular light waves, hinder the user’s circadian rhythm and eyesight,” Dr. Perez continued. “In the long term, this exposure to artificial light is known to have a negative impact on the human body. However, the SunLike Series natural spectrum LEDs create light with a spectrum that is close to sunlight, offering significant benefits for eye protection and accurate color reproduction, making it an ideal lighting source for architecture, thus we expect it to become more popular in the field moving forward.”

Dr. Perez also stated, “Development in light fixtures which use natural light sources such as SunLike Series LEDs, will revolutionize future standards and design, as the construction industry applies even stricter standards to provide people with good quality light. As such, companies must focus on developing light fixtures that produce natural light.”

SunLike natural spectrum LED technology, developed by Seoul Semiconductor and Toshiba Materials, was awarded the Gold Award by Elektronik, a prestigious German magazine specializing in electronic components that has the largest number of subscribers in Germany.

Seoul Semiconductor global marketing group executive vice president Caleb Won said, “The researchers who were awarded the Nobel Prize in Physiology in 2017 identified the genes that govern the circadian rhythm, which controls the main functions of human behavior, including the level of hormones, sleeping, body temperature, and metabolism. Their research clearly shows the importance of maintaining the 24-hour cycle circadian rhythm formed by natural sunlight.”

Won continued, “This Symposium presented scientific, objective evidence on the impact of light on our circadian rhythm, sleep, and health. It was a meaningful opportunity to increase attention and awareness on the need for light fixtures that offer natural light, and to contemplate future directions for lighting. The SunLike Series LEDs, which recreate light that closely matches the natural spectrum of sunlight, promises to be the next-generation light source to lead the era of human-centric lighting.”

About TRI-R technology

TRI-R is a registered trademark of Toshiba Material Co., Ltd. It is a natural light LED light source technology that reproduces the spectrum of natural sunlight, developed by the concept and spectrum technology of natural light.

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – the world’s smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

# Trademarks

WICOP and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

Contact information

Europe
Seoul Semiconductor Europe GmbH
Ariane Heim
Tel: +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
or
North America
Seoul Semiconductor Inc.
Andrew Smith
Tel: +1 (901) 831-6614
Email: andrew.smith@seoulsemicon.com
or
Asia
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email: pr@seoulsemicon.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme